CJC-1295 + Ipamorelin: A Research Guide to Growth Hormone Peptides

Category: Research Guides • Reading time: ~7 minutes

CJC-1295 and ipamorelin are two of the most studied growth hormone-related peptides in preclinical research. While they work through different mechanisms, they interact with the same hormonal axis — the somatotropic axis — making them a frequently used combination in research exploring growth hormone secretion and downstream effects.

This guide explains what each compound is, how they work independently and together, and what the preclinical literature says about their effects.

The Somatotropic Axis: A Quick Primer

Before diving into the compounds themselves, it helps to understand the hormonal system they interact with. The somatotropic axis governs the production and release of growth hormone (GH) from the anterior pituitary gland. This system is regulated by two key hypothalamic hormones:

• GHRH (growth hormone-releasing hormone): stimulates the pituitary to release GH
• Somatostatin: inhibits GH release, acting as a counterbalance to GHRH

A third regulatory signal comes from ghrelin — a peptide produced primarily in the stomach — which activates GH secretagogue receptors (GHS-R) in the pituitary and hypothalamus to further stimulate GH release.

CJC-1295 works on the GHRH side of this system. Ipamorelin works on the ghrelin/GHS-R side. Together, they activate both stimulatory pathways simultaneously, which is why this combination is commonly explored in research studying GH secretion dynamics.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone). It was designed to resist enzymatic degradation while maintaining the receptor-binding activity of native GHRH. There are two research forms:

CJC-1295 Without DAC (also called Modified GRF 1-29)

This is a 29-amino-acid fragment of GHRH with four amino acid substitutions that increase stability. It has a half-life of approximately 30 minutes in biological systems, producing a pulse of GH release that more closely mimics natural secretion patterns. This form is preferred by researchers studying the physiological pulsatility of the GH axis.

CJC-1295 With DAC (Drug Affinity Complex)

The DAC version includes a chemical modification that allows the peptide to bind covalently to circulating albumin, dramatically extending its half-life to approximately 6–8 days. This produces sustained GH elevation rather than discrete pulses. Research with this form focuses on the effects of prolonged GH axis stimulation.

Understanding which form is being used is critical to interpreting research findings, as the two versions produce fundamentally different GH release profiles.

Research-grade CJC-1295 available here: Buy CJC-1295.

What Is Ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue — specifically, a selective GHS-R (growth hormone secretagogue receptor) agonist. It mimics the action of ghrelin at the pituitary GHS-R1a receptor, stimulating GH release through a pathway entirely separate from the GHRH pathway that CJC-1295 activates.

What makes ipamorelin particularly notable as a research tool is its selectivity. Unlike earlier GHRPs (growth hormone-releasing peptides) such as GHRP-2 and GHRP-6, ipamorelin produces minimal stimulation of cortisol, prolactin, and ACTH release. This cleaner receptor profile makes it useful for studying GH secretion in isolation, without the confounding effects of concurrent stress hormone activation.

Key properties of ipamorelin in preclinical research:

• Selective GHS-R1a agonist with minimal off-target hormonal stimulation
• Short half-life (~2 hours) producing a defined pulse of GH release
• Studied in models of muscle wasting, bone density, metabolism, and GH deficiency
• Low propensity for tachyphylaxis (receptor desensitisation) in animal studies

Research-grade ipamorelin available here: Buy Ipamorelin.

Why Are These Two Often Studied Together?

The combination of CJC-1295 and ipamorelin is one of the most researched peptide pairings in the growth hormone space. The rationale is mechanistic: each compound activates a distinct receptor pathway, and both pathways converge on GH release from the pituitary.

Studies using the combination have observed that co-administration produces a synergistic GH pulse — greater than either compound alone. This is consistent with the known physiology: maximal GH release occurs when both GHRH stimulation and ghrelin signalling are active simultaneously. The combination is therefore a useful research tool for:

• Studying maximal GH release capacity in experimental models
• Investigating the downstream effects of elevated GH on IGF-1 production, muscle, bone, and metabolism
• Comparing pulsatile (ipamorelin) vs sustained (CJC-1295 with DAC) GH stimulation
• Exploring interactions between the two arms of the somatotropic axis

Preclinical Research Overview

Research Area

Findings in Animal Models

GH Pulse Amplitude

Co-administration of GHRH analogues and GHRPs consistently produced larger GH pulses than either compound alone in rodent studies, confirming synergistic receptor activation.

IGF-1 Levels

Sustained GH stimulation (especially with DAC form) elevated circulating IGF-1 levels in animal models, which mediated downstream anabolic effects on muscle and bone tissue.

Muscle and Body Composition

Studies in aged or GH-deficient animal models showed improvements in lean mass, reduced adiposity, and increased muscle protein synthesis markers with GHRH/GHRP combinations.

Bone Density

Research in osteopenic animal models found increases in bone mineral density and trabecular bone volume with long-term GH axis stimulation via peptide combinations.

Metabolism

Effects on lipid metabolism, glucose handling, and insulin sensitivity have been observed in metabolic disease models, though results vary by protocol and disease state.

Handling and Storage

Both CJC-1295 and ipamorelin are supplied as lyophilised powder:

• Store at -20°C prior to reconstitution
• Reconstitute with bacteriostatic water — add water slowly, do not shake
• Store reconstituted solutions at 4°C and use within 30 days
• When using both compounds in the same research protocol, prepare and store separately

For detailed reconstitution instructions: Peptide Reconstitution Guide.

Browse Growth Hormone Peptides

View All Growth Hormone Peptides →

⚠️ Research Use Disclaimer

All peptides sold by Peptide Research Store are intended strictly for in vitro research and laboratory use only. They are not intended for human or veterinary use, consumption, or therapeutic application of any kind. These products have not been evaluated by Health Canada or the FDA for safety or efficacy in humans. By purchasing, you confirm you are a qualified researcher using products in accordance with all applicable laws.

Reviewed by the Peptide Research Store editorial team • Last updated: March 2026 • Sources: PubMed / NCBI